A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma

HSK31858 is being tested in a solid phase 2 design: randomized, double-blind, placebo-controlled, and multicenter, so the readout should be interpretable if execution is adequate. The primary endpoint, annualized asthma exacerbation rate over 24 weeks, is clinically meaningful and can support a clearly positive outcome when a drug has real activity. But it is also a relatively noisy endpoint for a mid-stage study. Exacerbation rates depend heavily on baseline severity, concomitant controller therapy, seasonality, and event adjudication, and a 24-week window may not generate enough events for clean separation unless the enrolled population is strongly exacerbation-prone. The record provides no mechanism, biomarker enrichment, dose-ranging context, or prior efficacy signal, so there is little trial-specific evidence to justify assuming a large effect. Operationally, the status still says Enrolling By Invitation even though estimated primary completion has just passed, which raises some risk of delay, under-enrollment, or a less mature dataset. Overall, this looks somewhat more likely to miss than hit.

HSK31858 is a DPP-1 inhibitor with strong Phase 2 bronchiectasis results (SAVE-BE: HR 0.40-0.52 for exacerbation reduction). However, this trial targets bronchial asthma — a fundamentally different disease. DPP-1 inhibition addresses neutrophilic inflammation, relevant to only a subset of asthma patients (neutrophilic/non-T2 endotype, ~20-30%). The trial does not appear to enrich for neutrophilic phenotype based on inclusion criteria (requires ICS+controller, ≥1 exacerbation, FEV1<80%, ACQ≥1.5), which recruits a broad moderate-to-severe asthma population. Phase 2 asthma trials with novel mechanisms frequently fail — even brensocatib has no asthma data. The exacerbation rate endpoint over 24 weeks in 219 patients may be underpowered if the drug only benefits a subpopulation. Base rate for Phase 2 success is ~30-35%, and asthma's heterogeneous pathophysiology with a novel, untested-in-asthma mechanism adds risk. The strong bronchiectasis signal is encouraging but insufficient to predict asthma success.

This is a Phase 2 trial for HSK31858 in bronchial asthma with a primary endpoint of annualized exacerbation rate over 24 weeks. Key observations: (1) Trial status shows 'Enrolling By Invitation' but daysToPrimaryCompletion is -11, indicating the primary completion date has passed, creating ambiguity about actual status; (2) No prior Phase 1 data or interim results are provided to assess efficacy signals; (3) Phase 2 asthma trials have moderate success rates but substantial failure risk due to dose-finding and efficacy validation challenges; (4) The exacerbation rate endpoint is clinically meaningful but requires sufficient sample size and duration to demonstrate statistical significance. Without enrollment updates, interim data, or prior human safety/efficacy signals from the sponsor, intrinsic probability defaults to roughly 50% — reflecting high uncertainty typical of early-phase readout predictions. The binary call is 'yes' at the threshold.

This is a Phase 2 asthma trial for a novel drug, HSK31858, from a Chinese sponsor. The primary endpoint is the annualized exacerbation rate over 24 weeks, a standard but challenging efficacy measure. The trial is still 'Enrolling By Invitation' and the estimated primary completion date has already passed (-11 days), suggesting enrollment or operational delays. For a novel mechanism in a competitive disease area with established biologics, Phase 2 proof-of-concept is uncertain. No prior positive data is mentioned. The operational delay adds to disclosure and execution risk. The intrinsic odds appear slightly below a coin flip.

Robust phase 2 design: randomized, double-blind, placebo-controlled, multicenter trial evaluating annualized asthma exacerbation rate over 24 weeks—a reliable, objective endpoint with clinical relevance and low placebo noise in moderate-severe asthma populations. Patient population targets bronchial asthma, likely uncontrolled moderate-to-severe cases suitable for exacerbation reduction, though exact criteria (e.g., FEV1, prior therapies) unspecified. No prior HSK31858 data provided; novel Haisco compound lacks established efficacy signals, facing ~25-35% historical phase 2 success in asthma due to disease heterogeneity, high placebo rates, and competitive bar. Sponsor Haisco (002653.SZ) has solid execution in China but elevated operational risks vs. global Big Pharma. Primary completion 11 days past (status: Enrolling By Invitation), implying minor delays or top-up but low disclosure/manipulation risk with imminent readout. Strong setup offset by prior uncertainty yields 38% YES.

This Phase 2 trial for HSK31858 in asthma is a high-risk endeavor. The primary endpoint is a reduction in annualized asthma exacerbation rate. While DPP4 inhibitors have shown promise in preclinical models, translating this mechanism into clinical efficacy in asthma has historically proven difficult, with many similar programs failing in Phase 2. The primary endpoint of exacerbation rate is a high bar for a Phase 2 study, which are often underpowered to detect differences in exacerbation rates. Furthermore, the sponsor, Haisco Pharmaceutical, lacks a strong track record of successful late-stage respiratory drug development, adding execution risk. The primary completion date passed in March 2026, but the status 'Enrolling by Invitation' suggests recruitment challenges or a struggle to meet endpoints. Given the high bar for efficacy in asthma and the lack of prior efficacy data, a negative outcome is the more probable outcome.

HSK31858 is a novel DPP-1 inhibitor for asthma, an indication where many agents have failed. Phase 2 asthma trials with exacerbation endpoints historically show ~40% placebo response rates, making signal detection difficult. The 24-week duration is adequate but the 11-day post-completion window with no data disclosure is concerning—positive trials typically announce topline quickly. Sponsor Haisco has limited respiratory track record. The primary endpoint (annualized exacerbation rate) requires substantial patient exposure; with enrollment still ongoing by invitation, power may be marginal. No prior Phase 1 asthma data is disclosed. Mechanistically, DPP-1 inhibition targets neutrophilic inflammation, which may not address the eosinophilic-dominant asthma population. Combined with the silent post-completion period suggesting potential data cleaning issues or underwhelming results, the intrinsic probability is below 50%.

The key driver for this high-conviction forecast is the trial's explicit inclusion criterion of a blood eosinophil count < 150/μL. This precisely selects for T2-low, neutrophilic asthma, avoiding the phenotypic dilution that historically causes novel asthma therapies to fail when T2-high (eosinophilic) patients are inadvertently included. HSK31858 is a selective DPP-1 inhibitor that blocks the activation of neutrophil serine proteases (NSPs). This exact mechanism has recently proven highly successful in bronchiectasis, another neutrophil-driven airway disease, where HSK31858 (in the Phase 2 SAVE-BE trial) and brensocatib both dramatically reduced annualized exacerbation rates. By matching a proven anti-neutrophilic mechanism of action with an enriched T2-low asthma population, the sponsor has effectively de-risked the primary endpoint (annualized exacerbation rate at 24 weeks). Furthermore, selecting patients with a history of recent exacerbations (≥1 in 12 months) and poorly controlled symptoms (ACQ-5 ≥ 1.5) ensures a sufficient baseline event rate to power the N=219 sample size. Given the validated mechanism, targeted trial design, and robust sample size, the probability of a positive outcome is well above historical averages for generic Phase 2 asthma trials.

The trial is in Phase 2, which has a relatively high failure rate. The primary endpoint is the annualized asthma exacerbation rate within 24 weeks, which may be subject to variability. The study is still enrolling, and the primary completion date is near, which reduces the risk of disclosure bias. However, the sample size and patient population details are not provided, making it difficult to fully assess the trial's potential. Given these factors, a 45% probability of a positive result seems reasonable.